A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasms

Interventions

DRUG: INCB160058
DRUG: Standard disease-directed therapy

Sponsor

Incyte Corporation